Key result
Intravenous streptokinase in acute myocardial infarction (where 75% had low baseline titres) resulted in antibody consumption within 24 hours and an IgG1 peak at day 14.
Why the study?
Does intravenous streptokinase induce a specific antibody response in patients with acute myocardial infarction?
Population
48 patients with acute myocardial infarction
Comparison
Intravenous streptokinase vs Baseline values and patients unsuitable for…
Design
Cohort
Follow-up
one year
Authors
Loading...
Streptokinase elicits sustained IgG1 response in AMI; extends immunogenicity data but leaves open implications for repeat dosing.
Observational (n=48)
No
Does intravenous streptokinase induce a specific antibody response in patients with acute myocardial infarction?
Treatment with streptokinase for acute myocardial infarction induces a secondary immune response with specific IgG1 antibodies peaking at 14 days and remaining elevated at one year.
Lynch et al. (1991) conducted an observational in acute myocardial infarction (n=48). Streptokinase was evaluated on Specific IgG and subclass IgG1 antibody response to streptokinase. Intravenous streptokinase in acute myocardial infarction (where 75% had low baseline titres) resulted in antibody consumption within 24 hours and an IgG1 peak at day 14.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: